Anti-ALK-1 antibody (ab10179)
- Datasheet
- References
- Protocols
Overview
-
Product nameAnti-ALK-1 antibody
See all ALK-1 primary antibodies -
DescriptionGoat polyclonal to ALK-1
-
Host speciesGoat
-
Tested applicationsSuitable for: WBmore details
-
Species reactivityReacts with: Human
-
Immunogen
Synthetic peptide corresponding to Human ALK-1 aa 491-503 (C terminal).
Sequence:C-KISNSPEKPKVIQ
(Peptide available asab23196) -
Positive control
- Lung and liver extracts.
-
General notes
Activin A receptor, type II-like 1 is a type I cell-surface receptor for the TGF-beta superfamily of ligands. ACVRL1 is most highly expressed in human placenta and lung. ACVRL1 deficiency causes hemorrhagic telangiectasia type 2 (HHT2; MIM 600376 ) also known as Rendu-Osler-Weber syndrome 2 (ORW2). Note: ACVRL1 is also known as ALK1 - not to be confused with the similarly named ALK (anaplastic lymphoma kinase).
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
-
Storage bufferPreservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA -
Concentration information loading... -
PurityImmunogen affinity purified
-
Purification notesPurified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
-
Primary antibody notesActivin A receptor, type II-like 1 is a type I cell-surface receptor for the TGF-beta superfamily of ligands. ACVRL1 is most highly expressed in human placenta and lung. ACVRL1 deficiency causes hemorrhagic telangiectasia type 2 (HHT2; MIM 600376 ) also known as Rendu-Osler-Weber syndrome 2 (ORW2). Note: ACVRL1 is also known as ALK1 - not to be confused with the similarly named ALK (anaplastic lymphoma kinase).
-
ClonalityPolyclonal
-
IsotypeIgG
-
Research areas
Associated products
-
Compatible Secondaries
-
Immunizing Peptide (Blocking)
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab10179 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | Use a concentration of 1 - 3 µg/ml. Detects a band of approximately 60 kDa (predicted molecular weight: 56 kDa).Can be blocked with Human ALK-1 peptide (ab23196). |
Target
-
FunctionOn ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta. May bind activin as well.
-
Involvement in diseaseDefects in ACVRL1 are the cause of hereditary hemorrhagic telangiectasia type 2 (HHT2) [MIM:600376]; also known as Osler-Rendu-Weber syndrome 2 (ORW2). HHT2 is an autosomal dominant multisystemic vascular dysplasia, characterized by recurrent epistaxis, muco-cutaneous telangiectases, gastro-intestinal hemorrhage, and pulmonary, cerebral and hepatic arteriovenous malformations; all secondary manifestations of the underlying vascular dysplasia.
-
Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
Contains 1 GS domain.
Contains 1 protein kinase domain. -
Cellular localizationMembrane.
- Information by UniProt
-
Database links
- Entrez Gene: 94 Human
- Omim: 601284 Human
- SwissProt: P37023 Human
- Unigene: 591026 Human
-
Alternative names
- Activin A receptor antibody
- Activin A receptor type II like 1 antibody
- Activin A receptor, type II like kinase 1 antibody
see all
Images
-
Western blot - Anti-ALK-1 antibody (ab10179)Anti-ALK-1 antibody (ab10179) at 2 µg/ml + MCF7 lysate at 35 µg
Developed using the ECL technique.
Predicted band size: 56 kDa
Observed band size: 60 kDa why is the actual band size different from the predicted?
Protocols
Datasheets and documents
References
ab10179 has not yet been referenced specifically in any publications.
